115 related articles for article (PubMed ID: 37802206)
1. Circulating sNinj1 as a novel predictor of prognosis and severity in hepatocellular carcinoma.
Yan L; Su W; Gan D; Li D; Mai L; Wang B; Wang L; Peng L; Jiang L; Wang Z; Hu Q; Chen W
Clin Chim Acta; 2023 Oct; 550():117581. PubMed ID: 37802206
[TBL] [Abstract][Full Text] [Related]
2. Circulating miR-148/152 family as potential biomarkers in hepatocellular carcinoma.
Wang F; Ying H; He B; Pan Y; Sun H; Wang S
Tumour Biol; 2016 Apr; 37(4):4945-53. PubMed ID: 26531720
[TBL] [Abstract][Full Text] [Related]
3. The predictive values of serum dickkopf-1 and circulating tumor cells in evaluating the efficacy of transcatheter arterial chemoembolization treatment on hepatocellular carcinoma.
Wu X; Yang C; Yu H; Cao F; Shan Y; Zhao W
Medicine (Baltimore); 2019 Jul; 98(30):e16579. PubMed ID: 31348291
[TBL] [Abstract][Full Text] [Related]
4. C-reactive protein may be a prognostic factor in hepatocellular carcinoma with malignant portal vein invasion.
Kim JM; Kwon CH; Joh JW; Ko JS; Park JB; Lee JH; Kim SJ; Paik SW; Park CK
World J Surg Oncol; 2013 Apr; 11():92. PubMed ID: 23618082
[TBL] [Abstract][Full Text] [Related]
5. Postintervention Interleukin-6 (IL-6) Level, Rather than the Pretreatment or Dynamic Changes of IL-6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
Wu Y; Fan W; Xue M; Zhong B; Zhang S; Wang Y; Yao W; Zhao Y; Li J
Oncologist; 2019 Dec; 24(12):e1489-e1495. PubMed ID: 31249138
[TBL] [Abstract][Full Text] [Related]
6. Circulating miR-21 serves as a serum biomarker for hepatocellular carcinoma and correlated with distant metastasis.
Guo X; Lv X; Lv X; Ma Y; Chen L; Chen Y
Oncotarget; 2017 Jul; 8(27):44050-44058. PubMed ID: 28477010
[TBL] [Abstract][Full Text] [Related]
7. Serum Insulin-Like Growth Factor-1 (IGF-1): a Novel Prognostic Factor for Early Recurrence of Hepatocellular Carcinoma (HCC).
Yao Y; Mao W; Dong M; Yang D; Li W; Chen Y
Clin Lab; 2017 Feb; 63(2):261-270. PubMed ID: 28182337
[TBL] [Abstract][Full Text] [Related]
8. MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence.
Liu M; Hu Q; Tu M; Wang X; Yang Z; Yang G; Luo R
J Exp Clin Cancer Res; 2018 Jan; 37(1):10. PubMed ID: 29357919
[TBL] [Abstract][Full Text] [Related]
9. Serum MicroRNAs as Potential Biomarkers for Early Diagnosis of Hepatitis C Virus-Related Hepatocellular Carcinoma in Egyptian Patients.
Motawi TK; Shaker OG; El-Maraghy SA; Senousy MA
PLoS One; 2015; 10(9):e0137706. PubMed ID: 26352740
[TBL] [Abstract][Full Text] [Related]
10. Circulating miRNA-199a and miRNA-122 Levels as Potential Diagnostic and Prognostic Biomarkers for Hepatocellular Carcinoma.
Wu J; Wu Y; Luo Y; Li X; Lin N; Yang X; Lin Y; Chen M
Ann Clin Lab Sci; 2020 Mar; 50(2):219-227. PubMed ID: 32366560
[TBL] [Abstract][Full Text] [Related]
11. High level of intercellular adhesion molecule-1 affects prognosis of patients with hepatocellular carcinoma.
Zhu PP; Yuan SG; Liao Y; Qin LL; Liao WJ
World J Gastroenterol; 2015 Jun; 21(23):7254-63. PubMed ID: 26109813
[TBL] [Abstract][Full Text] [Related]
12. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
Feng H; Li B; Li Z; Wei Q; Ren L
BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
[TBL] [Abstract][Full Text] [Related]
13. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Nomograms Stratify Survival of Patients with Hepatocellular Carcinoma Without Portal Vein Tumor Thrombosis After Curative Resection.
Fu YP; Yi Y; Huang JL; Jing CY; Sun J; Ni XC; Lu ZF; Cao Y; Zhou J; Fan J; Qiu SJ
Oncologist; 2017 May; 22(5):561-569. PubMed ID: 28438885
[TBL] [Abstract][Full Text] [Related]
15. Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma.
Sun Y; Zhu S; Wu Z; Huang Y; Liu C; Tang S; Wei L
Oncotarget; 2017 Apr; 8(14):23427-23435. PubMed ID: 28178643
[TBL] [Abstract][Full Text] [Related]
16. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.
Masuda K; Ono A; Aikata H; Kawaoka T; Nelson Hayes C; Teraoka Y; Daijo K; Nakamura-Inagaki Y; Morio K; Fujino H; Kan H; Uchida T; Masaki K; Kobayashi T; Nakahara T; Makokha GN; Zhang Y; Nagaoki Y; Miki D; Tsuge M; Hiramatsu A; Imamura M; Abe-Chayama H; Kawakami Y; Ochi H; Chayama K
J Gastroenterol; 2018 Jan; 53(1):107-118. PubMed ID: 28474222
[TBL] [Abstract][Full Text] [Related]
17. Expression characteristics and diagnostic value of annexin A2 in hepatocellular carcinoma.
Zhang HJ; Yao DF; Yao M; Huang H; Wu W; Yan MJ; Yan XD; Chen J
World J Gastroenterol; 2012 Nov; 18(41):5897-904. PubMed ID: 23139605
[TBL] [Abstract][Full Text] [Related]
18. Epithelial-mesenchymal transition markers expressed in circulating tumor cells in hepatocellular carcinoma patients with different stages of disease.
Li YM; Xu SC; Li J; Han KQ; Pi HF; Zheng L; Zuo GH; Huang XB; Li HY; Zhao HZ; Yu ZP; Zhou Z; Liang P
Cell Death Dis; 2013 Oct; 4(10):e831. PubMed ID: 24091674
[TBL] [Abstract][Full Text] [Related]
19. Elevated serum plasma fibrinogen is associated with advanced tumor stage and poor survival in hepatocellular carcinoma patients.
Zhang X; Long Q
Medicine (Baltimore); 2017 Apr; 96(17):e6694. PubMed ID: 28445272
[TBL] [Abstract][Full Text] [Related]
20. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
